Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner

Neuropharmacology

Volumn 89, Issue , 2015, Pages 298-307

  Zádor, Ferenc ^a   Lénárt, Nikolett ^a   Csibrány, Balázs ^a   Sántha, Miklós ^a   Molnár, Máté ^b   Tuka, Bernadett ^b   Samavati, Reza ^a   Klivényi, Péter ^b   Vécsei, László ^b   Marton, Annamária ^a   Vizler, Csaba ^a   Nagy, György M ^c   Borsodi, Anna ^a   Benyhe, Sándor ^a   Páldy, Eszter ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c First Departmentof Pathology an Experimental Cancer Research University of Semmelweis   (Hungary)

Author keywords

Cannabinoid receptor type 1; Elevated plus maze; Kappa opioid receptor; Light dark box; Mouse forebrain; Rimonabant

Indexed keywords

CANNABINOID 1 RECEPTOR; DYNORPHIN; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; NORBINALTORPHIMINE; RIMONABANT; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; PIPERIDINE DERIVATIVE; PROTEIN BINDING; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHEMICAL BINDING; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; FEMALE; FOREBRAIN; LIGAND BINDING; LOW DRUG DOSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; ANIMAL; C57BL MOUSE; CHO CELL LINE; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; GENETICS; KNOCKOUT MOUSE; MAZE TEST; METABOLISM; PSYCHOLOGY; SWIMMING; VISUAL ADAPTATION;

ADAPTATION, OCULAR; ANALGESICS, OPIOID; ANIMALS; ANXIETY; CANNABINOID RECEPTOR ANTAGONISTS; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NARCOTIC ANTAGONISTS; PIPERIDINES; PROSENCEPHALON; PROTEIN BINDING; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, KAPPA; SWIMMING;

EID: 84908399517     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.10.008     Document Type: Article

References (83)

1. C. Arévalo, R. de Miguel, and R. Hernández-Tristán Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol. Biochem. Behav. 70 2001 123 131
2. U. Arvidsson, M. Riedl, S. Chakrabarti, L. Vulchanova, J.H. Lee, A.H. Nakano, X. Lin, H.H. Loh, P.Y. Law, and M.W. Wessendorf The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids Proc. Natl. Acad. Sci. U. S. A. 92 1995 5062 5066
3. T. Avidor-Reiss, R. Zippel, R. Levy, D. Saya, V. Ezra, J. Barg, N. Matus-Leibovitch, and Z. Vogel kappa-Opioid receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opioid treatments FEBS Lett. 361 1995 70 74
4. R. Bals-Kubik, A. Ableitner, A. Herz, and T.S. Shippenberg Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats J. Pharmacol. Exp. Ther. 264 1993 489 495
5. R.M. Beckstead, V.B. Domesick, and W.J. Nauta Efferent connections of the substantia nigra and ventral tegmental area in the rat Brain Res. 175 1979 191 217
6. S. Benyhe, J. Farkas, G. Tóth, and M. Wollemann Met5-enkephalin-Arg6-Phe7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain J. Neurosci. Res. 48 1997 249 258
7. B. Berger, A.K. Rothmaier, F. Wedekind, J. Zentner, T.J. Feuerstein, and R. Jackisch Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex Br. J. Pharmacol. 148 2006 795 806 10.1038/sj.bjp.0706782
8. C.E. Beyer, J.M. Dwyer, M.J. Piesla, B.J. Platt, R. Shen, Z. Rahman, K. Chan, M.T. Manners, T.A. Samad, J.D. Kennedy, B. Bingham, and G.T. Whiteside Depression-like phenotype following chronic CB1 receptor antagonism Neurobiol. Dis. 39 2010 148 155 10.1016/j.nbd.2010.03.020
9. N.J.M. Birdsall Class A GPCR heterodimers: evidence from binding studies Trends Pharmacol. Sci. 31 2010 499 508 10.1016/j.tips.2010.08.003
10. M. Bourin, and M. Hascoët The mouse light/dark box test Eur. J. Pharmacol. 463 2003 55 65
11. C.S. Breivogel, G. Griffin, V. Di Marzo, and B.R. Martin Evidence for a new G protein-coupled cannabinoid receptor in mouse brain Mol. Pharmacol. 60 2001 155 163
12. M.R. Bruchas, B.B. Land, and C. Chavkin The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors Brain Res. 1314 2010 44 55 10.1016/j.brainres.2009.08.062
13. R. Capasso, F. Borrelli, M.G. Cascio, G. Aviello, K. Huben, J.K. Zjawiony, P. Marini, B. Romano, V. Di Marzo, F. Capasso, and A.A. Izzo Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors Br. J. Pharmacol. 155 2008 681 689 10.1038/bjp.2008.294
14. W.A. Carlezon, C. Béguin, J.A. DiNieri, M.H. Baumann, M.R. Richards, M.S. Todtenkopf, R.B. Rothman, Z. Ma, D.Y. Lee, and B.M. Cohen Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats J. Pharmacol. Exp. Ther. 316 2006 440 447 10.1124/jpet.105.092304
15. W.A. Carlezon, C. Béguin, A.T. Knoll, and B.M. Cohen Kappa-opioid ligands in the study and treatment of mood disorders Pharmacol. Ther. 123 2009 334 343 10.1016/j.pharmthera.2009.05.008
16. V. Castagné, P. Moser, S. Roux, and R.D. Porsolt Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice Curr. Protoc. Neurosci. 2011 10.1002/0471142301.ns0810as55 (Chapter 8), Unit 8.10A
17. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713 10.1016/S0140-6736(07)61721-8
18. R. Cinar, and M. Szücs CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells J. Pharmacol. Exp. Ther. 330 2009 567 574 10.1124/jpet.109.152710
19. M. De Zwaan, and J.E. Mitchell Opiate antagonists and eating behavior in humans: a review J. Clin. Pharmacol. 32 1992 1060 1072
20. D.G. Demuth, and A. Molleman Cannabinoid signalling Life Sci. 78 2006 549 563 10.1016/j.lfs.2005.05.055
21. D. Filliol, S. Ghozland, J. Chluba, M. Martin, H.W. Matthes, F. Simonin, K. Befort, C. Gavériaux-Ruff, A. Dierich, M. LeMeur, O. Valverde, R. Maldonado, and B.L. Kieffer Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses Nat. Genet. 25 2000 195 200 10.1038/76061
22. T.M. Fong, L.P. Shearman, D.S. Stribling, J. Shu, J. Lao, C.R.-R. Huang, J.C. Xiao, C.P. Shen, J. Tyszkiewicz, A.M. Strack, C. DeMaula, M.F. Hubert, A. Galijatovic-Idrizbegovic, R. Owen, A.C. Huber, and C.L. Lanning Pharmacological efficacy and safety profile of taranabant in preclinical species Drug Dev. Res. 70 2009 349 362 10.1002/ddr.20311
23. J. Fonseca, and N. Lambert Instability of a class A G protein-coupled receptor oligomer interface Mol. Pharmacol. 75 2009 1296 1299 10.1124/mol.108.053876
24. A. Frazer Pharmacology of antidepressants J. Clin. Psychopharmacol. 17 Suppl. 1 1997 2S 18S
25. B. Gaszner, V. Kormos, T. Kozicz, H. Hashimoto, D. Reglodi, and Z. Helyes The behavioral phenotype of pituitary adenylate-cyclase activating polypeptide-deficient mice in anxiety and depression tests is accompanied by blunted c-Fos expression in the bed nucleus of the stria terminalis, central projecting Edinger-Westphal nucleus Neuroscience 202 2012 283 299 10.1016/j.neuroscience.2011.11.046
26. J.P. Gong, E.S. Onaivi, H. Ishiguro, Q.R. Liu, P.A. Tagliaferro, A. Brusco, and G.R. Uhl Cannabinoid CB2 receptors: immunohistochemical localization in rat brain Brain Res. 1071 2006 10 23 10.1016/j.brainres.2005.11.035
27. J. González-Maeso GPCR oligomers in pharmacology and signaling Mol. Brain 4 2011 10.1186/1756-6606-4-20
28. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur. J. Neurosci. 16 2002 1395 1398 10.1046/j.1460-9568.2002.02192.x
29. V.L. Haller, D.L. Stevens, and S.P. Welch Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase Eur. J. Pharmacol. 600 2008 50 58 10.1016/j.ejphar.2008.08.005
30. H. Hamm The many faces of G protein signaling J. Biol. Chem. 273 1998 669 672
31. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
32. A.G. Hohmann, and M. Herkenham Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study Synapse 37 2000 71 80 10.1002/(SICI)1098-2396(200007)37 1<71::AID-SYN8>3.0.CO;2-K
33. A.C. Howlett, M. Bidaut-Russell, W.A. Devane, L.S. Melvin, M.R. Johnson, and M. Herkenham The cannabinoid receptor: biochemical, anatomical and behavioral characterization Trends Neurosci. 13 1990 420 423
34. E.M. Hur, and K.T. Kim G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity Cell Signal. 14 2002 397 405
35. Y.L. Hurd Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain Neuroscience 72 1996 767 783
36. Z. Járai, J.A. Wagner, K. Varga, K.D. Lake, D.R. Compton, B.R. Martin, a M. Zimmer, T.I. Bonner, N.E. Buckley, E. Mezey, R.K. Razdan, A. Zimmer, and G. Kunos Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors Proc. Natl. Acad. Sci. U. S. A. 96 1999 14136 14141
37. B. Jordan, and L. Devi G-protein-coupled receptor heterodimerization modulates receptor function Nature 399 1999 697 700 10.1038/21441.G-protein-coupled
38. M. Kathmann, K. Flau, A. Redmer, C. Tränkle, and E. Schlicker Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors Naunyn. Schmiedeb. Arch. Pharmacol. 372 2006 354 361 10.1007/s00210-006-0033-x
39. B. Le Foll, and S.R. Goldberg Cannabinoid CB 1 receptor antagonists as promising new medications for drug dependence J. Pharmacol. Exp. Ther. 312 2005 875 883 10.1124/jpet.104.077974
40. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, F. Beslot, G.A. Böhme, A. Imperato, T. Pedrazzini, B.P. Roques, G. Vassart, W. Fratta, and M. Parmentier Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
41. S. Lee, D.H. Kim, S.H. Yoon, and J.H. Ryu Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus Neurosci. Lett. 467 2009 111 116 10.1016/j.neulet.2009.10.017
42. N. Lénárt, V. Szegedi, G. Juhász, A. Kasztner, J. Horváth, E. Bereczki, M.E. Tóth, B. Penke, and M. Sántha Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice PLoS One 7 2012 e46007 10.1371/journal.pone.0046007
43. J.R. Lever PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development Curr. Pharm. Des. 13 2007 33 49
44. S.H. Lockie, T.A. Czyzyk, N. Chaudhary, D. Perez-Tilve, S.C. Woods, B.J. Oldfield, M.A. Statnick, and M.H. Tschöp CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice Endocrinology 152 2011 3661 3667 10.1210/en.2011-1220
45. S.J. MacLennan, P.H. Reynen, J. Kwan, and D.W. Bonhaus Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors Br. J. Pharmacol. 124 1998 619 622 10.1038/sj.bjp.0701915
46. S.D. Mague, A.M. Pliakas, M.S. Todtenkopf, H.C. Tomasiewicz, Y. Zhang, W.C. Stevens, R.M. Jones, P.S. Portoghese, and W.A. Carlezon Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats J. Pharmacol. Exp. Ther. 305 2003 323 330 10.1124/jpet.102.046433
47. A. Mansour, C. Fox, H. Akil, and S. Watson Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications Trends Neurosci. 18 1995 22 29
48. G. Marsicano, and B. Lutz Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain Eur. J. Neurosci. 11 1999 4213 4225 10.1046/j.1460-9568.1999.00847.x
49. M.J. Millan The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review Eur. J. Pharmacol. 500 2004 371 384 10.1016/j.ejphar.2004.07.038
50. F.A. Moreira, and J.A.S. Crippa The psychiatric side-effects of rimonabant Os efeitos-colaterais psiquiátricos do rimonabanto 31 2009 145 153
51. M. Navarro, E. Hernández, R.M. Muñoz, I. del Arco, M.A. Villanúa, M.R. Carrera, and F. Rodríguez de Fonseca Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat Neuroreport 8 1997 491 496
52. W.M. Oldham, and H.E. Hamm Heterotrimeric G protein activation by G-protein-coupled receptors Nat. Rev. Mol. Cell Biol. 9 2008 60 71 10.1038/nrm2299
53. R.S. Padwal, and S.R. Majumdar Drug treatments for obesity: orlistat, sibutramine, and rimonabant Lancet 369 2007 71 77 10.1016/S0140-6736(07)60033-6
54. E. Páldy, E. Bereczki, M. Sántha, T. Wenger, A. Borsodi, A. Zimmer, and S. Benyhe CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain Neurochem. Int. 53 2008 309 316 10.1016/j.neuint.2008.08.005
55. E. Páldyová, E. Bereczki, M. Sántha, T. Wenger, A. Borsodi, and S. Benyhe Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors Neurochem. Int. 52 2008 321 328 10.1016/j.neuint.2007.06.033
56. R.G. Pertwee Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists Curr. Med. Chem. 17 2010 1360 1381
57. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, M.R. Elphick, P.J. Greasley, H.S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, and R.A. Ross International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 Pharmacol. Rev. 62 2010 588 631 10.1124/pr.110.003004.588
58. A. Pfeiffer, V. Brantl, A. Herz, and H.M. Emrich Psychotomimesis mediated by kappa opiate receptors Science 233 1986 774 776
59. A. Ramos Animal models of anxiety: do I need multiple tests' Trends Pharmacol. Sci. 29 2008 493 498 10.1016/j.tips.2008.07.005
60. M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Néliat, and D. Caput SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240 244
61. C. Schwarzer 30 years of dynorphins-new insights on their functions in neuropsychiatric diseases Pharmacol. Ther. 123 2009 353 370 10.1016/j.pharmthera.2009.05.006
62. K.A. Seely, L.K. Brents, L.N. Franks, M. Rajasekaran, S.M. Zimmerman, W.E. Fantegrossi, and P.L. Prather AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies Neuropharmacology 63 2012 905 915 10.1016/j.neuropharm.2012.06.046
63. L.A. Selbie, and S.J. Hill G protein-coupled- receptor cross-talk: the fine-tuning of multiple pathways Trends Pharmacol. Sci. 19 1998 87 93
64. T.S. Shippenberg, A. LeFevour, and V.I. Chefer Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction CNS Neurol. Disord. Drug Targets 7 2008 442 453
65. 35S]guanylyl-5′-O-(gamma-thio)-triphosphate binding in guinea pig brain J. Comp. Neurol. 386 1997 562 572
66. 35S]thio]-triphosphate binding Proc. Natl. Acad. Sci. U. S. A. 92 1995 7242 7246
67. 3H]leucine and horseradish peroxidase Brain Res. 178 1979 17 40 10.1016/0006-8993(79)90085-4
68. P.B. Smith, S.P. Welch, and B.R. Martin Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice J. Pharmacol. Exp. Ther. 268 1994 1381 1387
69. I. Svízenská, P. Dubový, and A. Sulcová Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review Pharmacol. Biochem. Behav. 90 2008 501 511 10.1016/j.pbb.2008.05.010
70. M. Tanaka, M. Yoshida, H. Emoto, and H. Ishii Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies Eur. J. Pharmacol. 405 2000 397 406
71. K. Thibault, D. Carrel, D. Bonnard, K. Gallatz, A. Simon, M. Biard, S. Pezet, M. Palkovits, and Z. Lenkei Activation-dependent subcellular distribution patterns of CB1 cannabinoid receptors in the rat forebrain Cereb. Cortex 23 2013 2581 2591 10.1093/cercor/bhs240
72. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells Mol. Pharmacol. 47 1995 848 854
73. N.P. Tsai, J. Bi, H.H. Loh, and L.N. Wei Netrin-1 signaling regulates de novo protein synthesis of kappa opioid receptor by facilitating polysomal partition of its mRNA J. Neurosci. 26 2006 9743 9749 10.1523/JNEUROSCI.3014-06.2006
74. N.P. Tsai, J. Bi, and L.N. Wei The adaptor Grb7 links netrin-1 signaling to regulation of mRNA translation EMBO J. 26 2007 1522 1531 10.1038/sj.emboj.7601598
75. E.T. Tzavara, R.J. Davis, K.W. Perry, X. Li, C. Salhoff, F.P. Bymaster, J.M. Witkin, and G.G. Nomikos The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Br. J. Pharmacol. 138 2003 544 553 10.1038/sj.bjp.0705100
76. L. Urigüen, F. Berrendero, C. Ledent, R. Maldonado, and J. Manzanares Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice Eur. J. Neurosci. 22 2005 2106 2110 10.1111/j.1460-9568.2005.04372.x
77. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, D. Piomelli, J.S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K.D. Patel, and K.A. Sharkey Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 2005 10.1126/science.1115740
78. M.L. Wadenberg A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist CNS Drug Rev. 9 2003 187 198
79. D. Walentiny, R. Vann, and J. Warner Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents Psychopharmacology (Berl.) 210 2010 275 284 10.1007/s00213-010-1827-6
80. A.A. Walf, and C.A. Frye The use of the elevated plus maze as an assay of anxiety-related behavior in rodents Nat. Protoc. 2 2007 322 328 10.1038/nprot.2007.44
81. M.R. Yeomans, and R.W. Gray Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect Physiol. Behav. 62 1997 15 21
82. F. Zádor, D. Kocsis, A. Borsodi, and S. Benyhe Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity Neurochem. Int. 67 2014 14 22 10.1016/j.neuint.2013.12.005
83. F. Zádor, F. Ötvös, S. Benyhe, A. Zimmer, and E. Páldy Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors Neurochem. Int. 61 2012 378 388 10.1016/j.neuint.2012.05.015